Table 1.
Baseline characteristics
| SELECT BC-CONFIRM* | Combined analysis* | |||
|---|---|---|---|---|
| S-1 | Anthracycline | S-1 | Standard | |
| Characteristics | (n = 113) | (n = 109) | (n = 419) | (n = 395) |
| Median age (range) | 59.9 (31–75) | 61.0 (32–75) | 57.7 (29–75) | 58.2 (21–75) |
| Hormonal receptor status | ||||
| Positive | 92 (81.4) | 86 (78.9) | 315 (75.2) | 299 (75.7) |
| Negative | 21 (18.6) | 23 (21.1) | 90 (21.5) | 90 (22.8) |
| Liver metastasis | ||||
| Yes | 47 (41.6) | 46 (42.2) | 150 (35.8) | 142 (35.9) |
| No | 66 (58.4) | 63 (57.8) | 269 (64.2) | 253 (64.1) |
| HER2** | ||||
| Negative | 102 (90.3) | 97 (89.0) | 384 (91.6) | 361 (91.4) |
| Unknown | 11 (9.7) | 12 (11.0) | 35 (8.4) | 34 (8.6) |
| Components of (neo)adjuvant treatment | ||||
| Oral fluoropyrimidine | 12 (10.6) | 14 (12.8) | 47 (11.2) | 53 (13.4) |
| Taxane# | 31 (27.4) | 30 (27.5) | 111 (26.5) | 110 (27.8) |
| Endocrine therapy | 64 (56.6) | 65 (59.6) | 233 (55.6) | 235 (59.5) |
| Metastasis after surgery | ||||
| <2 yrs | 14 (12.4) | 16 (14.7) | 74 (17.7) | 73 (18.5) |
| ≥2 yrs, 5 < yrs | 30 (26.5) | 26 (23.9) | 133 (31.7) | 124 (31.4) |
| ≥5 yrs | 42 (37.2) | 42 (38.5) | 136 (32.5) | 128 (32.4) |
| Unknown | 0 (0.0) | 0 (0.0) | 2 (0.5) | 0 (0.0) |
| Without surgery | 27 (23.9) | 25 (22.9) | 74 (17.7) | 70 (17.7) |
*There were no significant differences between the groups in any of the characteristics listed in this table.
**HER2 denotes the human epidermal growth factor receptor.
#Taxane was docetaxel or paclitaxel.